JP2020519250A - 副甲状腺ホルモン融合ポリペプチド - Google Patents

副甲状腺ホルモン融合ポリペプチド Download PDF

Info

Publication number
JP2020519250A
JP2020519250A JP2019558571A JP2019558571A JP2020519250A JP 2020519250 A JP2020519250 A JP 2020519250A JP 2019558571 A JP2019558571 A JP 2019558571A JP 2019558571 A JP2019558571 A JP 2019558571A JP 2020519250 A JP2020519250 A JP 2020519250A
Authority
JP
Japan
Prior art keywords
fusion polypeptide
amino acid
seq
acid sequence
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019558571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519250A5 (https=
Inventor
ウィルキンソン，イアン
ロス，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield filed Critical University of Sheffield
Publication of JP2020519250A publication Critical patent/JP2020519250A/ja
Publication of JP2020519250A5 publication Critical patent/JP2020519250A5/ja
Priority to JP2022202078A priority Critical patent/JP2023027315A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019558571A 2017-04-28 2018-04-27 副甲状腺ホルモン融合ポリペプチド Pending JP2020519250A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022202078A JP2023027315A (ja) 2017-04-28 2022-12-19 副甲状腺ホルモン融合ポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1706781.0A GB201706781D0 (en) 2017-04-28 2017-04-28 Parathyroid hormone fusion polypeptide
GB1706781.0 2017-04-28
PCT/GB2018/051120 WO2018197895A2 (en) 2017-04-28 2018-04-27 Parathyroid hormone fusion polypeptide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022202078A Division JP2023027315A (ja) 2017-04-28 2022-12-19 副甲状腺ホルモン融合ポリペプチド

Publications (2)

Publication Number Publication Date
JP2020519250A true JP2020519250A (ja) 2020-07-02
JP2020519250A5 JP2020519250A5 (https=) 2021-06-10

Family

ID=59011076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019558571A Pending JP2020519250A (ja) 2017-04-28 2018-04-27 副甲状腺ホルモン融合ポリペプチド
JP2022202078A Pending JP2023027315A (ja) 2017-04-28 2022-12-19 副甲状腺ホルモン融合ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022202078A Pending JP2023027315A (ja) 2017-04-28 2022-12-19 副甲状腺ホルモン融合ポリペプチド

Country Status (7)

Country Link
US (2) US11344606B2 (https=)
EP (1) EP3609913A2 (https=)
JP (2) JP2020519250A (https=)
CN (1) CN110546159B (https=)
CA (1) CA3061088A1 (https=)
GB (1) GB201706781D0 (https=)
WO (1) WO2018197895A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706781D0 (en) * 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
SG11202106223RA (en) * 2019-01-11 2021-07-29 Radius Health Inc Methods for detecting neutralizing antibodies to parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) analog
CN111876388A (zh) * 2020-07-24 2020-11-03 赛瑞诚(苏州)生物科技有限公司 一种骨和骨组织靶向外泌体及其制备方法和应用
CN118126197B (zh) * 2024-03-19 2025-02-25 康众(广东)生物医药有限公司 一种重组pth融合蛋白及其构建方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
JPH11285388A (ja) 1998-04-03 1999-10-19 Jcr Pharmaceuticals Co Ltd キメラレセプター発現細胞とその用途
AU2001257169C1 (en) 2000-04-21 2011-06-16 Tufts Medical Center, Inc. G-protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
WO2008124166A2 (en) 2007-04-09 2008-10-16 The Board Of Trustees Of The University Of Arkansas Fusion proteins of collagen-binding domain and parathyroid hormone
GB0717985D0 (en) 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CN105153313A (zh) 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
GB201104285D0 (en) * 2011-03-15 2011-04-27 Asterion Ltd Modified receptor fusion proteins
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
ES2695161T3 (es) 2011-12-14 2019-01-02 Univ Arkansas Administración de agentes terapéuticos mediante una proteína de unión a colágeno
WO2013108235A1 (en) 2012-01-20 2013-07-25 Lupin Limited Stabilized pth formulation
CA2919477A1 (en) * 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
JP6805174B2 (ja) 2015-05-12 2020-12-23 アメリカ合衆国 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むａａｖ分離株及び融合タンパク質
GB201706781D0 (en) * 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Development of a long-acting granulocyte colony stimulating factor molecule", BRITISH JOURNAL OF HAEMATOLOGY, vol. Vol.173, Suppl.1, pp.25-26, 42, JPN6022006626, 2016, ISSN: 0005014534 *
JOURNAL OF BONE AND MINERAL RESEARCH, vol. Vol.22, No.10, pp.1534-1547, JPN6022006625, 2007, ISSN: 0005014533 *
JOURNAL OF BONE AND MINERAL RESEARCH, vol. Vol.31, No.7, pp.1405-1412, JPN6022006628, 2016, ISSN: 0005014536 *
日本内科学会雑誌, vol. Vol.88, No.7, pp.1271-1276, JPN6022006627, 1999, ISSN: 0005014535 *

Also Published As

Publication number Publication date
US20220218790A1 (en) 2022-07-14
JP2023027315A (ja) 2023-03-01
WO2018197895A3 (en) 2019-01-17
CN110546159B (zh) 2023-08-22
WO2018197895A2 (en) 2018-11-01
US20200164033A1 (en) 2020-05-28
CN110546159A (zh) 2019-12-06
GB201706781D0 (en) 2017-06-14
US11344606B2 (en) 2022-05-31
CA3061088A1 (en) 2018-11-01
EP3609913A2 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
US20220218790A1 (en) Parathyroid hormone fusion polypeptide
JP5865359B2 (ja) エキセンジン−４の融合タンパク質およびその類似体、これらの調製方法および使用
EP2277890B1 (en) Peptide capable of extending half-life of peptide of interest in plasma
RU2473554C2 (ru) Слитые белки гормона роста
KR102692516B1 (ko) 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
US10822386B2 (en) Insulin analogues with enhanced stability and reduced mitogenicity
RS51319B (sr) GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
MX2014008668A (es) Formulacion de pth estabilizada.
US10703792B2 (en) Insulin analogues with selective signaling properties and reduced mitogenicity
EP3604538A1 (en) Long-acting adrenomedullin derivative
CN105884901A (zh) 具持续控制血糖含量功能的重组人血清白蛋白/胰高糖素类肽融合蛋白
US20220135640A1 (en) Cortistatin or an analogue thereof as a pharmaceutically active agent in latent form
Chen et al. Bioactivity and pharmacokinetics of two human serum albumin–thymosin α1-fusion proteins, rHSA-Tα1 and rHSA-L-Tα1, expressed in recombinant Pichia pastoris
RU2471808C2 (ru) Полипептиды модифицированного гормона роста
Draghia-Akli et al. Plasmid-based expression technology using growth hormone releasing hormone: a novel method for physiologically stimulating long-term growth hormone secretion
Rand-Weaver et al. A rapid procedure for the isolation of bioactive growth hormone
Delgado Mora et al. Cortistatinor an analogue thereof as a pharmaceutically active agent in latent form
LARKINS HUMAN INSULIN 1
KR20170069997A (ko) 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도
JPH09216832A (ja) 成人用ヒト成長ホルモン剤
CN101128213A (zh) 胰腺β细胞再生的促进剂以及在胰腺β细胞中生产胰岛素的促进剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221219

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221219

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230203

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230207

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230317

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230322